CEFOTAN® (Colfotan for Injection, USP)

**Indications**

For the treatment of infections caused by beta-lactamase-producing organisms and those caused by beta-lactamase-negative organisms. It is indicated for the treatment of infections caused by Pseudomonas aeruginosa and other organisms that may produce beta-lactamase.

**Contraindications**

CEFOTAN® should not be used in patients with a history of penicillin allergy. It is contraindicated in patients with a history of beta-lactamase-producing organisms.

**Warnings**

CEFOTAN® should be used in patients with a history of penicillin allergy.

**Precautions**

CEFOTAN® should be used with caution in patients with a history of penicillin allergy. It should be used with caution in patients with a history of beta-lactamase-producing organisms.

**Adverse Reactions**

The most common side effects of CEFOTAN® include diarrhea, nausea, and vomiting.

**Dosage and Administration**

CEFOTAN® (colfotan for injection, USP) is supplied in single-use vials containing 100 mg of Cefotan®. The recommended dosage is 200 mg every 24 hours for adults and children over 1 month of age.

**Clinical Pharmacology**

CEFOTAN® (colfotan for injection, USP) is a broad-spectrum, third-generation cephalosporin.

**Plasma Concentrations after Intravenous Dose**

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Concentration (mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>30</td>
<td>4</td>
</tr>
</tbody>
</table>

**Pharmacokinetics**

CEFOTAN® is rapidly absorbed following intravenous administration. It has a short half-life and is eliminated primarily by renal excretion.

**Microbiology**

CEFOTAN® is active against Gram-positive and Gram-negative bacteria, including staphylococci, streptococci, neisseria, pseudomonas, klebsiella, and escherichia.

**Pharmacology**

CEFOTAN® has a high degree of protein binding and is highly concentrated in the cerebrospinal fluid.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

CEFOTAN® has not been shown to be carcinogenic, mutagenic, or impair fertility in animals.

**Clinical Trials**

CEFOTAN® has been shown to be effective in treating a variety of infections, including urinary tract infections, respiratory infections, and skin and soft tissue infections.

**Nursing Considerations**

CEFOTAN® should be used with caution in patients with impaired renal function. Monitoring of renal function is recommended.

**Patient Counseling**

Instruct patients to report any side effects, such as diarrhea, nausea, or vomiting.

**Drug Interactions**

CEFOTAN® may interact with other medications, such as anticoagulants, digoxin, and loop diuretics.

**Overdosage**

Overdosage of CEFOTAN® may result in hypotension, diarrhea, nausea, and vomiting.

**Dosage Forms**

CEFOTAN® is available in a single-use vial containing 100 mg of Cefotan®.

**Storage**

CEFOTAN® should be stored at room temperature and protected from light.

**References**

CEFOTAN® has been studied extensively in clinical trials, and the data are reported in the literature.

**References**

